Pharmasset Inc.

Plus: Xtalpi, Solid and Arcus all raise cash

How changing the model for science funding to include investing in development could speed biomedical progress

BioCentury’s 2023 Financial Markets Preview

The case for being bolder and taking risks on early clinical deals

Friends, colleagues and peers pay tribute to John Martin

Atea led the pack of IPOs priced in the final week before the U.S. election, trading up 26% to $30.34 on its first day of trading Friday after raising $300 million. The upsized offering valued

Cell therapy play SQZ also sets terms for NASDAQ IPO

Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain

Gilead’s largest takeout ever adds to a string of cancer deals in 2020